Evidence map›Paper›PMID 30745981›Full record

ArticleOpen access Macedonian journal of medical sciences2019

Successful Treatment of Vitiligo Vietnamese Patients with Vitilinex® Herbal Bio-Actives in Combination with Phototherapy.

Thuong Nguyen Van, Trang Trinh Minh, Doanh Le Huu, Sau Nguyen Huu, Tung Vu Thanh, Nghi Dinh Huu, Van Tran Cam, My Le Huyen, Khang Tran Hau, Hao Nguyen Trong and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Open access Macedonian journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Thuong Nguyen VanNational Hospital of Dermatology and Venereology, Hanoi, Vietnam.
Trang Trinh MinhNational Hospital of Dermatology and Venereology, Hanoi, Vietnam.
Doanh Le HuuNational Hospital of Dermatology and Venereology, Hanoi, Vietnam.
Sau Nguyen HuuNational Hospital of Dermatology and Venereology, Hanoi, Vietnam.
Tung Vu ThanhNational Hospital of Dermatology and Venereology, Hanoi, Vietnam.
Nghi Dinh HuuNational Hospital of Dermatology and Venereology, Hanoi, Vietnam.
Van Tran CamNational Hospital of Dermatology and Venereology, Hanoi, Vietnam.
My Le HuyenNational Hospital of Dermatology and Venereology, Hanoi, Vietnam.
Khang Tran HauNational Hospital of Dermatology and Venereology, Hanoi, Vietnam.
Hao Nguyen TrongHCMC Hospital of Dermato-Venereology, Ho Chi Minh City, Vietnam.
Marco GandolfiUnit of Dermatology, University of Parma, Parma, Italy.
Francesca SatolliUnit of Dermatology, University of Parma, Parma, Italy.
Claudio FelicianiUnit of Dermatology, University of Parma, Parma, Italy.
Michael TirantUniversity of Rome G. Marconi, Rome, Italy.
Aleksandra VojvodicDepartment of Dermatology and Venereology, Military Medical Academy of Belgrade, Belgrade, Serbia.
Torello LottiUniversity of Rome G. Marconi, Rome, Italy.
National Hospital of Pediatrics · VNUniversity of Parma · ITMarconi University · ITHCMC Hospital of Dermato Venereology · VNMilitary Medical Academy · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVitiligo is an acquired pigmentary disease, that causes progressive loss of melanocytes, resulting in hypopigmented skin patches. Current treatments aim at stopping the disease progression and achieving repigmentation of the amelanotic areas. Corticosteroids, surgery, topical immunomodulators, total depigmentation of normal pigmented skin and phototherapy are current treatment options for vitiligo although phototherapy remains the treatment of choice. There is no documented evidence that herbal bio-active products may also be effective treatment options for vitiligo.

aimThis study aimed to investigate the efficacy and safety of Vitilinex® (herbal bio- actives) alone and in combination with UVB narrowband (311 nm) phototherapy, in the treatment of localised stable or active forms of vitiligo. MATERIAL AND

methodsSixty two subjects with mean age 34.5 years (range: 18-58 years) with mild to moderate vitiligo, consisting of 36 females and 26 males were randomly divided into three treatment groups - Group A (13 females, 10 males) treated with Vitilinex® alone; Group B (12 females, 11 males) were treated with Vitilinex® in combination with narrowband UVB (311 nm) phototherapy for 15 seconds, using a handheld lamp and Group C (8 females, 8 males) were treated with nbUVB (311 nm) phototherapy alone, for 15 seconds over a 12-week period.

resultsIn Group A, 9 patients (39%) achieved outstanding improvement with a re-pigmentation rate higher than 75%, with 2 patients experiencing total repigmentation. 6 patients (26%) had marked improvement with a repigmentation rate between 50-75% while 5 patients (22%) showed a moderate response between 25-50% re-pigmentation rate. 3 patients (13%) had minimal or no improvement. In Group B, 16 patients (69.5%) achieved outstanding improvement with a re-pigmentation rate higher than 75%, with 12 patients experiencing total re-pigmentation. 4 patients (17.5 %) achieved a marked improvement with a re-pigmentation rate between 50-75%; 2 patients (8.7%) showed a moderate response with a re-pigmentation rate between 25-50%. 1 (4.3%) patient had minimal or no improvement. In Group C, 6 patients (37.5%) achieved a re-pigmentation rate higher than 75%, with 2 patients experiencing total re-pigmentation. 4 patients (25%) achieved marked improvement with a re-pigmentation rate between 50-75% while 3 patients (18.75%) had a re-pigmentation rate between 25-50%. 3 patients (18.75%) had minimal or no improvement.

conclusionVitilinex® herbal bio-actives in combination with nbUVB is a more effective treatment option for vitiligo with 87% of the patients achieving a re-pigmentation rate higher than 50%, compared to Vitilinex® alone (65%) or nbUVB alone (62.5%).

Indexed as

Bio-activesPhototherapyRe-pigmentationUVB narrow band (311 nm)Vitiligo

Identifiers

PMID30745981
PMCPMC6364738
OpenAlexW2912451311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.